现代肿瘤医学
現代腫瘤醫學
현대종류의학
Journal of Modern Oncology
2015年
20期
2984-2987
,共4页
乔占兵%李泉旺%韩苏军%杨静哲%陈瑞廷%姜敏%孙韬%胡凯文%王金万%陶石
喬佔兵%李泉旺%韓囌軍%楊靜哲%陳瑞廷%薑敏%孫韜%鬍凱文%王金萬%陶石
교점병%리천왕%한소군%양정철%진서정%강민%손도%호개문%왕금만%도석
晚期肾癌%干扰素%舒尼替尼%免疫%不良反应%生存率
晚期腎癌%榦擾素%舒尼替尼%免疫%不良反應%生存率
만기신암%간우소%서니체니%면역%불량반응%생존솔
advanced kidney cancer%interferon%sunitinib%immunity%adverse reactions%survival
目的：对比免疫药物及传统药物在晚期肾癌治疗中的价值。方法：晚期肾癌患者120例根据随机抽签法分为治疗组与对照组各60例，所有患者都手术根除切除，对照组术后给予舒尼替尼靶向药物治疗，治疗组术后给予干扰素－α免疫药物治疗，跟踪时间有一个月。结果：两组的有效率为88．3％、66．7％，与之前做对比，治疗组效果明显好（P ＜0．05），治疗后血清 CD3和 CD4值比治疗前明显高（P ＜0．05），而且治疗组治疗后的血清 CD3和 CD4值高于对照组（P ＜0．05）。治疗过程治疗组的恶心、呕吐、疲乏等症状的总体发生情况明显低于对照组（P ＜0．05），所有不良反应经对症治疗后症状消退。治疗后随访调查1年，治疗组的半年与1年生存率分别为100．0％和96．7％，对照组为91．7％和85．0％，治疗组的生存率比较高（P ＜0．05）。结论：相对于传统药物治疗，免疫药物在晚期肾癌治疗中的应用能使得机体免疫功能得到部分恢复，从而提高治疗疗效，降低不良反应的发生，促进生存率的提高。
目的：對比免疫藥物及傳統藥物在晚期腎癌治療中的價值。方法：晚期腎癌患者120例根據隨機抽籤法分為治療組與對照組各60例，所有患者都手術根除切除，對照組術後給予舒尼替尼靶嚮藥物治療，治療組術後給予榦擾素－α免疫藥物治療，跟蹤時間有一箇月。結果：兩組的有效率為88．3％、66．7％，與之前做對比，治療組效果明顯好（P ＜0．05），治療後血清 CD3和 CD4值比治療前明顯高（P ＜0．05），而且治療組治療後的血清 CD3和 CD4值高于對照組（P ＜0．05）。治療過程治療組的噁心、嘔吐、疲乏等癥狀的總體髮生情況明顯低于對照組（P ＜0．05），所有不良反應經對癥治療後癥狀消退。治療後隨訪調查1年，治療組的半年與1年生存率分彆為100．0％和96．7％，對照組為91．7％和85．0％，治療組的生存率比較高（P ＜0．05）。結論：相對于傳統藥物治療，免疫藥物在晚期腎癌治療中的應用能使得機體免疫功能得到部分恢複，從而提高治療療效，降低不良反應的髮生，促進生存率的提高。
목적：대비면역약물급전통약물재만기신암치료중적개치。방법：만기신암환자120례근거수궤추첨법분위치료조여대조조각60례，소유환자도수술근제절제，대조조술후급여서니체니파향약물치료，치료조술후급여간우소－α면역약물치료，근종시간유일개월。결과：량조적유효솔위88．3％、66．7％，여지전주대비，치료조효과명현호（P ＜0．05），치료후혈청 CD3화 CD4치비치료전명현고（P ＜0．05），이차치료조치료후적혈청 CD3화 CD4치고우대조조（P ＜0．05）。치료과정치료조적악심、구토、피핍등증상적총체발생정황명현저우대조조（P ＜0．05），소유불량반응경대증치료후증상소퇴。치료후수방조사1년，치료조적반년여1년생존솔분별위100．0％화96．7％，대조조위91．7％화85．0％，치료조적생존솔비교고（P ＜0．05）。결론：상대우전통약물치료，면역약물재만기신암치료중적응용능사득궤체면역공능득도부분회복，종이제고치료료효，강저불량반응적발생，촉진생존솔적제고。
Objective:To compare the value of immune drugs and traditional medicines in the treatment of ad-vanced renal cell carcinoma.Methods:All 120 patients with advanced renal cell carcinoma based on randomly were equally divided into treatment group and control group.All patients had surgical resection eradication,the control group were given sunitinib targeted drug therapy,the treatment group were given interference Su -αimmune therapy. Results:The response rates in the treatment group and the control group were 88.3% and 66.7% (P <0.05).The serum CD3 and CD4 values after treatment were significantly higher than before treatment (P <0.05),while the val-ue of serum CD3 and CD4 treatment group after treatment were significantly higher (P <0.05).Both groups had no serious side effects,but the overall incidence of adverse events of nausea,vomiting,fatigue,in the treatment group were significantly lower than the control group (P <0.05).Followed -up survey after 1 year of treatment,six months and 1 year survival rate were 100.0% and 96.7% in the treatment group,91.7% and 85.0% in the control group (P <0.05).Conclusion:Compared with traditional medications,immune drugs in the treatment of advanced renal cell carcinoma can make partial restoration of immune function,thereby improve treatment efficacy and reduce adverse reactions,and ultimately promote the improvement of survival.
